Clinical trial technology companies Medidata Solutions and Aris Global announced the availability of an integrated solution that provides data-sharing between the Medidata Rave® system for electronic data capture, management and reporting and ARISg™, a solution for pharmacovigilance and clinical safety. The solution leverages Medidata’s Rave Safety Gateway, a configurable EDC-to-Safety system interface, to automatically transmit safety-related patient data collected in Medidata Rave directly into ARISg to help reduce risk, redundant data entry and eliminate the costly and time-sensitive burden of collecting and reconciling safety data.
“While Aris Global offers agCapture™, an EDC solution, we also see the value in giving customers the opportunity to leverage the Rave Safety Gateway to address their critical business challenges. The combined use of ARISg and Medidata Rave, leveraging Rave Safety Gateway, addresses the time-sensitive and safety-critical process of alerting regulatory agencies to potential safety events,” said Jeffrey Yablon, Vice President, Sales Aris Global.
A key purpose of clinical trials, as well as being a major obligation of the sponsor, is to monitor patients for serious adverse events (SAEs) and to collect and transmit reports in a timely manner. Even today, much of the collection of that data takes place outside other automated processes in a clinical trial, such as EDC systems like Medidata Rave. The traditional process involves phone conversations, paper forms and faxes between sites and sponsors, as well as manual keying of data into the sponsors’ safety system like ARISg, which helps collect, code, analyze and submit the information to regulatory agencies and license partners on a timely basis.
By instantly transferring safety-related data from the Medidata Rave EDC system to the ARISg safety reporting system, this solution helps eliminate duplicative entry, reduce SAE reconciliation efforts and chances for errors and expedite reporting time.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.